La vendita allo scoperto per Cadrenal Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cadrenal Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cadrenal Therapeutics (NASDAQ:CVKD) Azioni, Report sulle vendite allo scoperto

Cadrenal Therapeutics

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics Inc

Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 89.66 percent decrease over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $1.39 million which missed the analyst consensus estimate of $1.48 million by 6.01 percent. This is a 30.98 percent increase over sales of $1.06 million the same period last year.

Earnings

News

NYXH

Nyxoah Q3 EPS $(0.55) Misses $(0.46) Estimate, Sales $1.39M Miss $1.48M Estimate

Retail Sales

FTEK

Fuel Tech Inc Announced Orders From New And Existing Customers Totaling ~$2M

e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) shares are climbing after the company reported its second-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41786513/e-l-f-beauty-announces-second-quarter-fiscal-2025-results">details from the report.  </a>
The Details: e.l.f. Beauty reported quarterly earnings of 77 cents per share, which beat the analyst consensus estimate of 42 cents. Quarterly revenue came in at $301.1 million, which beat the analyst consensus estimate of $285.76 million and is an increase over sales of $215.5 million from the same period last year.
e.l.f. said its gross margin increased approximately 40 basis points to 71%, primarily driven by cost savings, favorable foreign exchange impacts and price increases in the company&#8217;s international markets, partially offset by mix and higher transportation costs.
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;Q2 marked another quarter of consistent, category-leading growth. In Q2, we delivered 40% net sales growth, fueled by 195 basis points of market share gains in the U.S. and 91% net sales growth internationally,&#8221; said Tarang Amin, e.l.f. Beauty&#8217;s CEO.
&#8220;This was our 23rd consecutive quarter of both net sales growth and market share gains. We continue to make progress across color cosmetics, skincare and international and believe our unique areas of advantage will fuel our ability to win in fiscal 2025 and beyond,&#8221; Amin added.
Outlook: e.l.f. Beauty raised its fiscal year 2025 net sales outlook to a range of $1.315 billion to $1.335 billion and now sees earnings of between $3.47 and $3.53 per share for the year.
ELF Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, e.l.f. Beauty shares are up 13.24% after-hours at $117.95 at the time of publication Wednesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Courtesy of E.l.f. Beauty, Inc.

Movers

e.l.f. Beauty Stock Soars After Strong Q2 Earnings Beat: Details

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. The company reported quarterly sales of $315.119 million which beat the analyst consensus estimate of $310.218 million by 1.58 percent. This is a 28.75 percent decrease over sales of $442.291 million the same period last year.

Earnings Beats

CCRN

Cross Country Healthcare Q3 2024 Adj. EPS $0.12 Beats $0.10 Estimate, Revenue From Services $315.119M Beat $310.218M Estimate

GFL Environmental Q3 2024 Adj. EPS C$0.23 Misses C$0.35 Estimate, Sales C$2.015B Miss C$2.052B Estimate

Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.29 by 20.69 percent. The company reported quarterly sales of $581.00 million which beat the analyst consensus estimate of $554.68 million by 4.75 percent. This is a 17.14 percent increase over sales of $496.00 million the same period last year.

Zillow Gr Q3 2024 Adj EPS $0.35 Beats $0.29 Estimate, Sales $581.00M Beat $554.68M Estimate

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.42 by 2.38 percent. The company reported quarterly sales of $2.653 billion which beat the analyst consensus estimate of $2.485 billion by 6.76 percent. This is a 3.67 percent increase over sales of $2.559 billion the same period last year.

Williams Companies Q3 2024 Adj. EPS $0.43 Beats $0.42 Estimate, Sales $2.653B Beat $2.485B Estimate

CS Disco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $36.27 million which missed the analyst consensus estimate of $36.33 million by 0.18 percent. This is a 3.79 percent increase over sales of $34.94 million the same period last year.

Earnings Misses

CS Disco Q3 Adj $(0.06) Beats $(0.09) Estimate, Sales $36.27M Miss $36.33M Estimate

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) raises FY2024 sales outlook from $1.05 billion-1.13 billion to $1.06 billion-1.13 billion.

Guidance

Emergent BioSolutions Raises FY2024 Sales Guidance from $1.05B-1.13B to $1.06B-1.13B

Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.57 by 14.65 percent. The company reported quarterly sales of $1.305 billion which beat the analyst consensus estimate of $1.267 billion by 3.01 percent. This is a 10.03 percent increase over sales of $1.186 billion the same period last year.

Marriott Vacations Q3 2024 Adj. EPS $1.80 Beats $1.57 Estimate, Sales $1.305B Beat $1.267B Estimate

TKO Group Holdings Sees FY24 Revenue To Upper End Of $2.67B-$2.745B Vs $2.758B Est.

Buybacks

AMPH

Amphastar Pharmaceuticals Expands Share Buyback Program By $50M To Offset Equity Compensation Dilution, With No Set End Date

SLR Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRC#NASDAQ">SLRC</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.42 by 7.14 percent. The company reported quarterly sales of $59.771 million which beat the analyst consensus estimate of $57.979 million by 3.09 percent. This is a 0.22 percent increase over sales of $59.641 million the same period last year.

SLRC

SLR Inv Q3 2024 GAAP EPS $0.45 Beats $0.42 Estimate, Sales $59.771M Beat $57.979M Estimate

A-Mark Precious Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.87 by 57.47 percent. The company reported quarterly sales of $2.715 billion which beat the analyst consensus estimate of $2.622 billion by 3.53 percent. This is a 9.26 percent increase over sales of $2.485 billion the same period last year.

AMRK

A-Mark Precious Metals Q1 2025 Adj. EPS $0.37 Misses $0.87 Estimate, Sales $2.715B Beat $2.622B Estimate

Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) is looking for Q4 Adj EPS of $0.32-0.52 vs $0.31 analyst estimate. seessales of $88.000 million-96.000 million vs $91.55 million estimate.

FARO

Faro Technologies Sees Q4 Adj EPS $0.32-0.52 vs $0.31 Est; Sees Sales $88.000M-96.000M vs $91.55M Est

Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) is looking for Q4 GAAP EPS of $(0.15)-0.05 vs $0.01 analyst estimate..

Faro Technologies Sees Q4 GAAP EPS $(0.15)-0.05 vs $0.01 Est

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported quarterly earnings of $0.96 per share which missed the analyst consensus estimate of $0.99 by 3.03 percent. The company reported quarterly sales of $191.20 million which missed the analyst consensus estimate of $194.69 million by 1.79 percent. This is a 5.90 percent increase over sales of $180.56 million the same period last year.

Amphastar Pharma Q3 2024 Adj EPS $0.96 Misses $0.99 Estimate, Sales $191.20M Miss $194.69M Estimate

ZipRecruiter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent. The company reported quarterly sales of $117.084 million which beat the analyst consensus estimate of $112.612 million by 3.97 percent. This is a 24.77 percent decrease over sales of $155.630 million the same period last year.

ZipRecruiter Q3 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $117.084M Beat $112.612M Estimate

The Company has identified and intends to realize annualized G&amp;A and operating expense savings of between $15 million and $20 million on a run-rate basis from the restructuring.
&nbsp;

Management

Sun Communities Plans Restructuring, John McLaren Returning As President; CEO Gary Shiffman Informs His Intention To Retire In 2025

Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.08 by 37.5 percent. The company reported quarterly sales of $186.600 million which beat the analyst consensus estimate of $181.637 million by 2.73 percent. This is a 21.52 percent increase over sales of $153.550 million the same period last year.

FRSH

Freshworks Q3 2024 Adj. EPS $0.11 Beats $0.08 Estimate, Sales $186.600M Beat $181.637M Estimate

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report) today and set a price targ...

Buy Rating Affirmed for Cadrenal Therapeutics on Strong Clinical and Financial Prospects

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cadrenal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cvkd-stock-quote/">CVKD</a>) just reported results for the first quarter of 2024.<ul><li>Cadrenal Therapeutics reported earnings per share of -10 cents. This was below the analyst estimate for EPS of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cvkd-stock-earnings-cadrenal-therapeutics-for-q1-of-2024/">CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report), retaining the price ta...

Optimistic Outlook for Cadrenal Therapeutics with Buy Rating Amidst Anticoagulation Market Shifts

The latest announcement is out from Cadrenal Therapeutics, Inc. (CVKD). At the 2024 Annual Meeting of Cadrenal Therapeutics, Inc., stockholders app...

Cadrenal Therapeutics Enhances Incentives and Adjusts Stock Plan

Cadrenal Therapeutics, Inc. (CVKD) has issued an update. Cadrenal Therapeutics has announced a partnership with Abbott to propel its key trial for ...

Cadrenal Therapeutics Partners with Abbott on Cardiac Trial

Abbott to collaborate with Cadrenal on anticoagulant tecarfarin

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cadrenal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cvkd-stock-quote/">CVKD</a>) just reported results for the second quarter of 2024.<ul><li>Cadrenal Therapeutics reported earnings per share of -15 cents. This was below the analyst estimate for EPS of -8 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cvkd-stock-earnings-cadrenal-therapeutics-for-q2-of-2024/">CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has shared an announcement. Cadrenal Therapeutics, Inc. has refreshed its investor presentation with detail...

Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy

Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. Cadrenal Therapeutics, a late-stage biopharmaceutical firm, has successfully...

Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin

Cadrenal Therapeutics (CVKD) has raised gross proceeds of approximately $5.1M through its at-the-market facility, selling an aggregate of 391,243 s...

Comments

Cadrenal Therapeutics

Vendite allo scoperto

Cadrenal Therapeutics (NASDAQ:CVKD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO